Company News
Guardant Health BTIG Top Pick, PT $195
BTIG reiterates Buy rating on Guardant Health, raising price target from $190 to $195.
Guardant reported Q2 revenue of $335 million, a 44% increase year‑on‑year, and 63% growth in core oncology volume
